Arabidopsis thaliana plants expressing Rift Valley fever virus antigens: Mice exhibit systemic immune responses as the result of oraladministration of the transgenic plants
2016 (English)In: Protein Expression and Purification, ISSN 1046-5928, E-ISSN 1096-0279, Vol. 127, 61-67 p.Article in journal (Refereed) Published
The zoonotic Rift Valley fever virus affects livestock and humans in Africa and on the Arabian Peninsula.The economic impact of this pathogen due to livestock losses, as well as its relevance to public health,underscores the importance of developing effective and easily distributed vaccines. Vaccines that can bedelivered orally are of particular interest.
Here, we report the expression in transformed plants (Arabidopsis thaliana) of Rift Valley fever virusantigens. The antigens used in this study were the N protein and a deletion mutant of the Gn glycoprotein.Transformed lines were analysed for specific mRNA and protein content by RT-PCR and Westernblotting, respectively. Furthermore, the plant-expressed antigens were evaluated for their immunogenicityin mice fed the transgenic plants. After oral intake of fresh transgenic plant material, a proportionof the mice elicited specific IgG antibody responses, as compared to the control animals that were fedwild-type plants and of which none sero-converted.
Thus, we show that transgenic plants can be readily used to express and produce Rift Valley Fever virusproteins, and that the plants are immunogenic when given orally to mice. These are promising findingsand provide a basis for further studies on edible plant vaccines against the Rift Valley fever virus.
Place, publisher, year, edition, pages
Elsevier, 2016. Vol. 127, 61-67 p.
Antigen production, Arabidopsis thaliana, Rift valley fever virus, Plant vaccine, Transformation
Immunology in the medical area Immunology Biochemistry and Molecular Biology Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Research subject Biochemistry; Immunology
IdentifiersURN: urn:nbn:se:oru:diva-51367DOI: 10.1016/j.pep.2016.07.003ISI: 000382181300009PubMedID: 27402440ScopusID: 2-s2.0-84978634507OAI: oai:DiVA.org:oru-51367DiVA: diva2:949160
ProjectsVaccinutveckling och vaccinproduktion
FunderKnowledge FoundationStiftelsen Olle Engkvist Byggmästare
Swedish International Development Cooperation Agency (SIDA)
Örebro University's Faculty for Business, Science and Technology
Sparbanksstiftelsen Nya2016-07-172016-07-172016-10-06Bibliographically approved